ARTV Stock Analysis: Artiva Biotherapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 471m USD | 12M Return: 500% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.96M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Artiva Biotherapeutics, Inc. (ARTV) is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead candidate, AlloNK, is an off-the-shelf NK cell therapy being evaluated across multiple autoimmune indications (including rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, and ANCA-associated vasculitis) and B-cell non-Hodgkin lymphoma. The pipeline also includes AB-201, an allogeneic anti-HER2 CAR-NK candidate for solid tumors (breast, gastric, esophageal, and bladder cancers), and AB-205, an allogeneic anti-CD5 CAR-NK candidate for hematological malignancies.
The company was incorporated in 2019 and is headquartered in San Diego, California. As a clinical-stage biotech, Artiva is pre-revenue and reliant on capital markets and partnerships to fund development, operating within the broader cell therapy subsector where NK cell platforms are positioned as a scalable, allogeneic alternative to autologous CAR-T therapies.
- AlloNK Phase 2 data readouts in lupus and B-cell lymphoma
- Cash burn accelerates as clinical trials expand across multiple autoimmune indications
- Competition intensifies from approved CAR-T therapies in B-cell lymphoma
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.76 > 0.02 and ΔFCF/TA -43.82 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.73 > 3% & CFO -77.9m > Net Income -87.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.7m) vs 12m ago 1.38% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.13%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 88.7m - Total Current Liabilities 10.9m) / Total Assets 106.0m |
| B: -3.34 (Retained Earnings -354.1m / Total Assets 106.0m) |
| C: -0.59 (EBIT TTM -87.1m / Avg Total Assets 148.6m) |
| D: 4.85 (Book Value of Equity 87.8m / Total Liabilities 18.1m) |
| Altman-Z'' = -4.92 = D |
As of July 08, 2026, the stock is trading at USD 9.48 with a total of 315,985 shares traded. Over the past week, the price has changed by -1.04%, over one month by +39.41%, over three months by +42.13% and over the past year by +500.00%.
Current recommended Stop Loss: 7.50 (which is 20.9% or 2.3 ATR below the current price).
Artiva Biotherapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ARTV.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.8 | 277.6% |
P/S = 8.1071
P/B = 5.3153
Revenue TTM = 0.0 USD
EBIT TTM = -87.1m USD
EBITDA TTM = -84.4m USD
Long Term Debt = 7.23m USD (estimated: total debt 10.3m - short term 3.04m)
Short Term Debt = 3.04m USD (from shortTermDebt, last quarter)
Debt = 10.3m USD (from shortLongTermDebtTotal, last quarter) (leases 10.3m already included)
Net Debt = -76.5m USD (calculated: Debt 10.3m - CCE 86.8m)
Enterprise Value = 394.8m USD (471.3m + Debt 10.3m - CCE 86.8m)
Interest Coverage Ratio = unknown (Ebit TTM -87.1m / Interest Expense TTM 0.0)
EV/FCF = -4.92x (Enterprise Value 394.8m / FCF TTM -80.2m)
FCF Yield = -20.31% (FCF TTM -80.2m / Enterprise Value 394.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.60m) / Revenue TTM)
Tobins Q-Ratio = 3.73 (Enterprise Value 394.8m / Total Assets 106.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -68.8m (EBIT -87.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.16 (Total Current Assets 88.7m / Total Current Liabilities 10.9m)
Debt / Equity = 0.12 (Debt 10.3m / totalStockholderEquity, last quarter 87.8m)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -76.5m / EBITDA -84.4m)
Debt / FCF = 0.95 (negative FCF - burning cash) (Net Debt -76.5m / FCF TTM -80.2m)
Total Stockholder Equity = 119.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.59% (Net Income -87.1m / Total Assets 106.0m)
RoE = -73.16% (Net Income TTM -87.1m / Total Stockholder Equity 119.0m)
RoCE = -68.97% (EBIT -87.1m / Capital Employed (Equity 119.0m + L.T.Debt 7.23m))
RoIC = -70.11% (negative operating profit) (NOPAT -68.8m / Invested Capital 98.1m)
WACC = 8.96% (E(471.3m)/V(481.6m) * Re(9.16%) + D(10.3m)/V(481.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 8.75%
[DCF] Fair Price = unknown (Cash Flow -80.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.01 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.52 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.43 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+29.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.81 | Chg30d=N/A | Revisions=+25% | GrowthEPS=-15.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +40% (up=2, down=0)